GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Cyclically Adjusted PS Ratio

Hansa Biopharma AB (OSTO:HNSA) Cyclically Adjusted PS Ratio : 54.21 (As of Jun. 05, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Cyclically Adjusted PS Ratio?

As of today (2024-06-05), Hansa Biopharma AB's current share price is kr51.50. Hansa Biopharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr0.95. Hansa Biopharma AB's Cyclically Adjusted PS Ratio for today is 54.21.

The historical rank and industry rank for Hansa Biopharma AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

OSTO:HNSA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 27.63   Med: 145   Max: 1849.23
Current: 52.18

During the past years, Hansa Biopharma AB's highest Cyclically Adjusted PS Ratio was 1849.23. The lowest was 27.63. And the median was 145.00.

OSTO:HNSA's Cyclically Adjusted PS Ratio is ranked worse than
92.66% of 504 companies
in the Biotechnology industry
Industry Median: 5.505 vs OSTO:HNSA: 52.18

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hansa Biopharma AB's adjusted revenue per share data for the three months ended in Mar. 2024 was kr1.063. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr0.95 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Hansa Biopharma AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Hansa Biopharma AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Cyclically Adjusted PS Ratio Chart

Hansa Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1,918.16 416.36 78.86 30.83

Hansa Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.50 59.46 45.14 30.83 30.59

Competitive Comparison of Hansa Biopharma AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Hansa Biopharma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Cyclically Adjusted PS Ratio falls into.



Hansa Biopharma AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Hansa Biopharma AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=51.50/0.95
=54.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Hansa Biopharma AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.063/132.2054*132.2054
=1.063

Current CPI (Mar. 2024) = 132.2054.

Hansa Biopharma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.013 100.432 0.017
201409 0.000 100.161 0.000
201412 0.006 100.225 0.008
201503 0.141 99.950 0.187
201506 0.016 99.995 0.021
201509 0.016 100.228 0.021
201512 0.054 100.276 0.071
201603 0.018 100.751 0.024
201606 0.017 101.019 0.022
201609 0.028 101.138 0.037
201612 0.016 102.022 0.021
201703 0.030 102.022 0.039
201706 0.020 102.752 0.026
201709 0.019 103.279 0.024
201712 0.028 103.793 0.036
201803 0.016 103.962 0.020
201806 0.024 104.875 0.030
201809 0.013 105.679 0.016
201812 0.035 105.912 0.044
201903 0.023 105.886 0.029
201906 0.015 106.742 0.019
201909 0.016 107.214 0.020
201912 0.030 107.766 0.037
202003 0.022 106.563 0.027
202006 0.016 107.498 0.020
202009 0.017 107.635 0.021
202012 0.086 108.296 0.105
202103 0.202 108.360 0.246
202106 0.102 108.928 0.124
202109 0.111 110.338 0.133
202112 0.346 112.486 0.407
202203 0.681 114.825 0.784
202206 0.593 118.384 0.662
202209 1.505 122.296 1.627
202212 0.667 126.365 0.698
202303 0.461 127.042 0.480
202306 0.699 129.407 0.714
202309 0.435 130.224 0.442
202312 0.954 131.912 0.956
202403 1.063 132.205 1.063

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hansa Biopharma AB  (OSTO:HNSA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Hansa Biopharma AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansa Biopharma AB (OSTO:HNSA) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines